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Abstract
INTRODUCTION—Drug targeting to sites of tissue injury, tumor or infection with limited
toxicity is the goal for successful pharmaceutics. Immunocytes (including mononuclear
phagocytes (dendritic cells, monocytes and macrophages), neutrophils, and lymphocytes) are
highly mobile; they can migrate across impermeable barriers and release their drug cargo at sites
of infection or tissue injury. Thus immune cells can be exploited as trojan horses for drug delivery.
AREAS COVERED IN THIS REVIEW—This paper reviews how immunocytes laden with
drugs can cross the blood brain or blood tumor barriers, to facilitate treatments for infectious
diseases, injury, cancer, or inflammatory diseases. The promises and perils of cell-mediated drug
delivery are reviewed, with examples of how immunocytes can be harnessed to improve
therapeutic end points.
EXPERT OPINION—Using cells as delivery vehicles enables targeted drug transport, and
prolonged circulation times, along with reductions in cell and tissue toxicities. Such systems for
drug carriage and targeted release represent a novel disease combating strategy being applied to a
spectrum of human disorders. The design of nanocarriers for cell-mediated drug delivery may
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Article Highlights
• Using cell-mediated drug delivery systems offers several advantages including: a) targeted drug transport to disease sites;
b) prolonged drug half-lives; c) time-controlled release of loaded drugs; and d) diminished drug immunogenicity and
cytoxicity profiles.
• The goals need to be achieved for successful cell-mediated drug delivery include: a) high drug loading into cell-carriers; b)
efficient preservation of entrapped therapeutic agents against disintegration and clearance in the host cells; c) drug
triggered release at the site of action; d) efficient homing of cell-carriers to a disease site; e) safety of cell-based drug
formulations for the whole organism.
• Two different approaches are utilized in cell-mediated drug delivery: genetically modified cell-carriers producing
therapeutically active molecules; and drug loaded cell-carriers used as “Trojan horses” to deliver the drug to the disease
side.
• Living cells for drug carriage and release represent a novel disease combating strategy that can be applied to a spectrum of
human infectious, cancerous, and degenerative disorders.
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differ from those used for conventional drug delivery systems; nevertheless, engaging different
defense mechanisms into drug delivery may open new perspectives for the active delivery of
drugs.
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Introduction
The development of targeted drug delivery is amongst the most important goals of
pharmaceutical research. Its realization can lead to improved therapeutic efficacy, reductions
in drug dosing intervals, and decreased toxicities. However, this is not a simple task as drug
homing to pathologically relevant disease sites has only recently been investigated.
Obstacles are substantial and include sustained time-based plasma concentrations and local
blood flow.
1. Promise and Perils of Cell-Mediated Drug Delivery
Using immunocytes, mononuclear phagocytes (MP; monocytes, macrophages, and dendritic
cells) lymphocytes, and neutrophils and stem cells as drug carrier systems offers several
advantages over common drug administration regimens. These include targeted drug
transport to disease sites; prolonged drug half-lives; time-controlled drug release; and
diminished drug immunogenicity and cytoxicity profiles. Immunocytes and stem cells
exhibit an intrinsic homing property enabling them to migrate to sites of injury,
inflammation, and tumor. In addition, they can act as Trojan horses carrying concealed drug
cargoes while migrating across impermeable barriers (for example, the blood brain or blood
tumor barriers) to sites of disease.
Despite such advantages, there is as yet limited success for several reasons. First, drug
loading in cell carriers is low. Second, there are limitations due to the ability of
immunocytes and stem cells to efficiently disintegrate and clear entrapped therapeutic
agents. Third, the loaded drug should not be prematurely released, but unloaded, in
continuous action, upon the cell's arrival to the site of action or disease. Fourth, the cell
carriers should migrate to the disease site in substantial quantities. This should not be
compromised during drug loading. Finally, all used formulations must be safe for both the
cell carrier and the organism.
Many of these limitations can be addressed by incorporation of drugs into protective
polymeric nanocarriers (liposomes and lipid nanoparticles 1-4, micelles 5-8, nanogels 9, 10,
nanospheres and nanocapsules 11, 12, solid nanoparticles and nanosuspensions 13-16, block
ionomer complexes 17, 18 or nanofibers and nanotubes 19, 20) that preserve drugs inside
subcellular organelles (Figure 1). The ideal drug carrier for cell-mediated delivery should
have optimal size, shape and surface characteristics; multivalent attachment; controlled drug
release; and biocompatibility. All these characteristics are essential for translating cell-
mediated drug delivery systems for human use.
Drug loading into cell-carriers—Nanocarriers commonly have a core-shell structure.
Their central part (such as aqueous pool of nanospheres, hydrophobic core of micelles, or
polyelectrolyte core of nanogels) permits drug entrapment. It is surrounded with a polymer
shell (or lipids in liposomes and lipid nanoparticles), which defines the nanocarrier
dispersion stability, circulation time and cell interactions 1-8, 10, 11, 13, 14, 17, 18. Both the
core and shell are crucial for successful cell-mediated delivery. For example, the surface
coating affects the ability of particles to internalize into the cells and therefore, affects the
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loading of cell-carriers. In general, charged nanocarriers are rapidly taken up by MP and
other immunocytes or stem cells compared to neutral nanoparticles 1, 21-25. The recognition
occurs by receptors located on the cell plasma membranes, in particular, mannose,
complement, and Fc receptors (MR, CR and FcR) 26-28. In general, MR recognize mannans,
as well as integrins (for example CD11b/CD18), CR interact with particles after nonspecific
complement opsonization, and FcR recognize particles after specific antibody opsonization
28. Furthermore, positively charged nanoparticles accumulate in MP to a greater extent than
negatively charged particles. Thus, positively charged nanoparticles prepared by high
pressure homogenization with antiretroviral drugs, indinavir (IDV), ritonavir (RTV), and
efavirenz (EFV) accumulate in MP at about two-fold greater than the same size negatively
charged carriers 14. Similar effect was reported for nanoparticles (“nanozymes”) comprising
of redox enzyme, catalase, and variant synthetic polyelectrolyte block copolymers 29.
Loading capacity of nanozymes comprising of positively-charged mono-polymers
(polyethyleneimine-(PEI) and poly-L-lysine- (PL) based) is greater than the nanozyme
prepared with negatively-charged block poly-L-glutamic acid (PGLU)-based copolymer,
This likely occurs due to the greater absorption and internalization of positively-charged
nanoparticles to negatively-charged outside plasma membrane of cell-carriers.
An electrostatically neutral and hydrophilic poly(ethylene glycol) (PEG) is perhaps the most
common shell-forming polymer currently used in injectable nanocarriers 30-32. Particularly,
commercial PEGylated liposome-encapsulated Dox, Doxil, is approved for use in the
treatment of recurrent ovarian cancer, AIDS-related Kaposi's sarcoma 33 and metastatic
breast cancer 34. However, PEG is by far not the only polymer that should be considered in
the context of the cell-mediated delivery, as it can limit cellular uptake as was demonstrated
for microspheres bearing high-density surface PEG chains that were resistant to
phagocytosis 35. Similar results were obtained with nanoparticles comprised of catalase and
positively charged polymers based on PEI 29. Thus, loading capacity of nanozymes without
PEG corona in MP was significantly greater than those with PEG. To this end, modification
of nanocarrier shell with specific vector moieties can provide for targeted cell delivery of
nanocarriers 1, 26, 36-38. In particular, modification of PEG shell of a poly(amidoamine)
nanoparticles (PAMAM) with streptavidin facilitates targeting to biotinylated T-cell markers
such as anti-CD3 or peptide/ major histocompatibility (MHC) complexes 39 (Figure 2).
Size and shape of nanocarriers are also of importance for cell uptake, although the
phagosome may have different sizes depending of the size of the particles, which can range
from as little as few hundred nanometers 35, 40, 41 to several of microns 42. For example,
murine bone marrow-derived macrophages accumulate IgG-opsonized latex beads greater
than 20 μm in diameter 43. Furthermore, particles with the size about 1μm were accumulated
at greater extent (2.56 fold) than smaller drug carriers at 500 μm 14.
A recent study by Champion et al. reported striking effects of shape of particles on
phagocytosis in alveolar rat macrophages 44. Polystyrene-based particles of more than
twenty shapes including spheres, rectangles, rods, worms, oblate ellipses, elliptical disks and
UFO-like particles were manufactured. The local particle shape at the point where it was
attached to the cell played the crucial role in phagocytosis. For example, a macrophage
attached to a sharper side of the ellipse would internalize the particle in a few minutes. In
contrast, a macrophage attached to a dull side would not internalize the same ellipse for
hours. Although, particle size played a reduced role in the initiation of the phagocytosis it
could of course affect its completion especially when the particle volume exceeded that of a
cell.
Drug preservation inside cells—The stability of the drug loaded into cell carriers
among other factors can depend on the intracellular trafficking of the nanocarriers. In
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general, drug-loaded nanocarriers need to avoid lysosomes to reduce drug disintegration
inside cells 14. In this regard, it is noteworthy that cationic and anionic nanoparticles show
divergent fates inside MP 38. For example, phagocytosis of cationic polyamine-coated
nanoparticles leads to the diminished phagosomal acidification when compared to anionic
protein-coated particles. Such cationic nanoparticles protect the incorporated drug against
lisosomal degradation 29, 38. Furthermore, loading of “nanozymes” containing positively-
charged block copolymers (PEI-PEG and PL-PEG) protected the enzyme in macrophages.
Increasing the amount of the block copolymer in the nanozyme formulation improved the
stability of the enzyme. In contrast, catalase loaded in a polyion complex with a negatively
charged block copolymer (PGLU-PEG) was degraded in macrophages to an even greater
extent than catalase loaded alone. Protection of the enzymatic activity inside carrier cells
may be, in part, due to a “proton sponge” effect of block copolymers 45, when an excess of
amino groups on the surface of the nanoparticles buffers acidification of the cell's endocytic
compartments. This serves to inhibit protease activity and decrease drug degradation 38. In
other words, a positively charged block-copolymer prevents phagosome-lysosomal
clearance functions and as a result, enzyme degradation.
In extreme case, intracellular drug degradation can be avoided by attaching the drug to the
surface of cell-carriers. This “back pack” approach would still provide targeted transport and
increased blood circulation along with the preserved drug activity. Thus, attaching avidin-
coated nanoparticles to the biotinylated plasma membrane can be achieved through the
avidin-biotin complex 46. Another possibility is red blood cells (RBCs) with attached drugs
on their surface 47. Specifically, glycoprotein A covalently conjugated to the surface of the
RBCs may provide extended half-life, controlled volume of distribution, and multivalent
therapeutic interactions. However, general limitations of the “back pack” approach may
include decreased loading of cell carriers, impeded drug release at the disease site, as well as
increased immunogenicity and toxicity.
Drug release from cell-carriers—Mechanism of nanoparticle unloading at the site of
action remains an active area of investigation. Controlled release of drugs from the cell-
carriers modulates the rate of drug appearance, dose and duration of exposure at the diseased
sites. To this end, utilizing cellular responses to various conditions could provide desired
triggered release. Obviously, targeting of cell-carriers and their prolonged residence at the
disease site should provide opportunities for drug unloading. In addition, MP, in particular,
are known to produce and store various compounds in intracellular vesicles, and liberate
them via exocytosis at the site of the disease. A similar mechanism can trigger release of
drug-loaded nanocarriers, when macrophages serve as drug delivery vehicles 48.
Furthermore, the drug release can be also triggered by the increase of intracellular
concentration of Ca2+ 49. Finally, mild hypothermia was shown to facilitate controlled
release of drug-loaded liposomes from macrophages in anti-cancer therapy 50.
Overall the structure and composition of protective nanocontainers play a crucial role in the
effectiveness of formulations for cell-based drug delivery systems. For example, our recent
studies indicate that structure of block copolymer used for catalase nanoformulation,
nanozyme, affect its cytotoxicity, loading and release capacities, as well as preservation of
catalase enzymatic activity inside cell-carriers 29. Thus, nanozymes containing a negatively-
charged block copolymer (PGLU-PEG/catalase) demonstrated low toxicity, high loading
capacity and effective release from macrophages. However, the polymer provided limited
protection of the enzyme against cell-associated protease degradation. In contrast,
nanozymes based on positively charged block copolymers, especially the PLs, showed
increased cytotoxicity and low loading and release rates, but were protective of the catalase.
Increasing the amount of positively-charged block-copolymer in nanozyme leaded to
protection of catalase enzymatic activity but substantially reduced loadings and release.
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Importantly, nanozymes with PEG corona show water stability, limited cytoxicity and
efficient catalase protection. Nonetheless, these formulations also demonstrated decreased
loading capacity and release rates. In addition, nanozymes based on mono-polymer (without
PEG corona) have higher loading and release levels, but did not protect catalase inside the
cell-carriers. Taken together, the most optimal nanozyme formulation was the one based on
positively charged block copolymers (PEI-PEG/catalase and PL-PEG/catalase) that
demonstrate the most efficient protection of catalase enzymatic activity along with relatively
high loading and release rates with limited cytotoxicity (Figure 3).
Homing of drug-loaded cell-carriers at disease sites—The numbers of cell-carriers
that can reach the disease site is especially crucial in the case of CNS disorders when drug-
loaded cells need to penetrate the blood brain barrier (BBB) to mediate therapeutic effect.
Many neurological diseases, such as Alzheimer's and Parkinson's diseases (AD and PD),
Prion disease, meningitis, encephalitis and HIV-associated neurocognitive disorders
(HAND), have in common an inflammatory component 51. The process of inflammation is
characterized by extensive MP recruitment. Notably, MP migrate toward the inflammation
site via the processes known as diapedesis and chemataxis 52. Such cells efficiently cross the
BBB due to their margination and extravasation properties causing barrier breakdown as a
consequence of brain inflammation53-57. Many reports in the literature indicate that blood
borne monocytes traffic primarily between adjacent endothelial cells, i.e. paracellularly
through the junctional complexes58, 59. Therefore, these cells can be loaded with a required
drug and administered intravenously to reach the brain. For example in an experimental
model of PD, considerable levels of catalase loaded into BMM were reported in 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated brains48. Approximately 2.1% of the
injected catalase dose was delivered to the brain during MPTP-associated inflammation.
Furthermore, several studies confirmed the migration of inflammatory-response cells, in
particular, bone-marrow-derived mesenchymal stromal cells toward injury sites such as
infarcted myocardium60, 61, spinal cord injury62, and cerebral ischemia63.
Neural stem cells (NSCs) were also suggested as drug delivery vehicles for gene therapy in
the CNS 64-66. Indeed, these cells are highly migratory and migrate to areas of brain
pathology including ischemic and neoplastic brain lesions that are commonly present in AD,
PD, brain cancer, stroke, and multiple sclerosis. How the mobility of stem cells are directed
is not understood, although NSCs express a wide variety of receptors that should enable
them to respond to many chemotactic signals present in brain pathologies (Figure 4) 66. In
particular, activated microglia induced NSCs migration to the brain. Delivery of various
neurotropic factors is in the focus of cell-mediated strategies for neurological diseases
treatment.
In regards to cell-mediated drug delivery of antineoplastic agents, MP are known to
accumulate in large numbers in vascular, hypoxic sites in cancer tumors, for example, in
breast and prostate carcinomas 67, 68. Hypoxia is widespread in malignant human tumors
due to their poorly organized vasculature. The cytokines released by tumor cells in response
to hypoxia and other physiological stresses usually attract macrophages and monocytes,
which should facilitate anticancer drug delivery using these cells as vehicles, avoiding
indiscriminate drug distribution and decreasing severe toxicity.
Finally, targeting to disease sites can be improved by drug-incorporated magnetic
nanoparticles loaded into the cell-carriers and followed by application of local magnetic
fields 37. Thus, albino rats with brain inflammation (induced by intrastratial microinjection
of human recombinant IL-1β) received intravenous injections of RGD-coated magnetic
liposomes and non-magnetic liposomes as a control. RGD peptide (i.e. small peptide
domane Arg-Gly-Asp) was used for selective binding by monocytes and neutrophils that
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express integrin receptors on their surface. Magnetic liposomes demonstrated about a ten-
fold increase in brain levels compared with non-magnetic controlled carriers when local
magnetic field was applied. In addition, magnetic neutrophils prepared in vitro target lungs
under magnetic guidance following intravenous injection 69. Moreover, drug loaded
magnetic liposomes can be targeted for selective and preferential presentation to blood
monocytes/neutrophils that result in both drug and magnetic incorporation into these cells
and can be guided to target tissue sites.
Safety of cell-mediated drug delivery systems—An obvious concern for
inflammatory-response cell based drug delivery relates to possible cytotoxic effects of cell-
carriers. MP attracted to the site of pathology by cytokines release reactive oxygen species
(ROS) that cause cell damage. Moreover, a number of therapeutic strategies for CNS
neurodegenerative disorders are based on the prevention of monocyte-macrophage
infiltration 70. Therefore, precluding cytotoxicities for cell-based drug formulations is a
requirement for formulation developments. Furthermore, genetically-modified and
immortalized cell-carriers show atypical characteristics, such as higher degree of
multipotency, which may increase the probability of tumor formation. Nevertheless, studies
so far report no cytotoxic effects after macrophage-mediated drug delivery in the brain of
healthy C57BL/6 mice adoptively transferred with macrophages carrying nanoformulated
catalase 71. In addition, propagation and expansion of immortalized and genetically-
modified cell-carriers should allow improve quality controls 66.
Cell-mediated drug delivery systems in clinical settings—Finally, developing
such methods in a clinical setting may be successful when cell-carriers are harvested from
peripheral blood by apheresis, then loaded with particles and re-infused into the patient. An
alternative approach may be harvesting stem cells from bone marrow, propagation them in
culture to obtain monocytes, and then loading the cells with a drug and adoptively
transferring them. This procedure will allow for expansion of the cell population, although
this would require a more invasive procedure. To this end, immortalization of cell-carriers
can allow propagation of cells with definable properties so that clonal populations with
particular traits can be established. Furthermore, drug loading into cell-carriers can be
achieved directly in the patient's peripheral blood, when nanoformulated drugs would be
injected and selectively taken up by circulating cell carriers. Targeting of such nanocarriers
could be achieved by coating the nanocarrier surface with the receptor-specific moieties
(e.g., folate, gelatin, fibronectin, A-protein, mannose, or RGD peptide), which is recognized
by specific MP surface receptors. Overall, chronic diseases are more suitable for this type of
drug delivery than pathologies that require acute intervention. Based on such considerations,
we now present some successful investigations using living cells as drug delivery vehicles
for therapeutics (Table 1).
2. Neurodegenerative disorders and cell-based carriage of therapeutic nanoparticles
AD and PD—The progressive impairment of short-term memory and emotional
disturbances that typify AD results from synaptic dysfunction and neuronal death in the
hippocampus and linked regions in the cerebral cortex and limbic system. Because of the
increasing numbers of affected people, there is an urgent need to develop strategies able to
interfere with disease progression and protect neurons. In this respect, delivery of
neurotrophic factors (NTFs) including nerve growth factor (NGF) 65, brain-derived
neurotropic factor (BDNF) 64, and choline acetyltransferase (ChAT) 72 is of urgent need. To
overcome limited drug transport across the BBB, direct brain implantation of cells
engineered to produce NTFs was developed 73. In particular, ciliary neurotrophic factor
delivered in cells implanted in the brain prevents Aβ oligomer-induced neuronal damage and
neurobehavioral impairments in mouse models of AD. In another study NSCs
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overexpressing ChAT cDNA targeted acetylcholine deficits 74. The ability cell-carriers,
placed by cortical transplants, to improve cognition was tested after induced cholinergic
lesions in rats. Significant improvements were recorded in Water maze acquisition as well as
in the retention and spatial probe trials 74. A robust enhancement of hippocampal synaptic
density, mediated by BDNF and delivered by NSCs was seen 75. NSCs ameliorated complex
behavioral deficits associated with AD pathology by BDNF. In these experiments the
intracranial transplantation of the cell-carriers were utilized.
Due to specific nigrostriatal degeneration, PD was one of the first targets for cell therapy
transplants. Fetal dopamine neurons were inoculated into the putamen, where the cells
worked as dopamine pumps as seen during systemic administration of L-DOPA 76. It was
suggested that the transplanted cells were gene therapy vehicles for dopamine delivery
rather than replacement neurons 76. Delivery of neurotropic factors such as glial cell-line
derived neurotropic factor (GDNF) or vascular endothelial growth factor (VGEF) in neural
stem cell transplants were tested in PD mouse models 77-79. GDNF was delivered in bone
marrow-derived macrophages to the effected brain 80. The cells were transduced ex vivo
with lentivirus expressing a GDNF gene driven by a synthetic macrophage-specific
promoter and then transplanted into recipient mice. Eight weeks after transplantation, the
mice were injected with MPTP for seven days to induce nigrostriatal neurodegeneration.
Macrophage GDNF treatments dramatically ameliorated MPTP-induced degeneration of
tyrosine hydroxylase (TH)-positive neurons seen in the substantia nigra and TH(+) terminals
in the striatum. This resulted in axon regeneration and reversed hypoactivity in the open
field test.
Development of novel CNS drug delivery using macrophages carriers for delivery of the
antioxidant enzyme, catalase, in MPTP mice was reported by our laboratories 48, 71. In this
system, nanoformulated catalase (nanozyme) was obtained by coupling the enzyme to a
cationic block copolymer, PEI-PEG, leading to a polyion complex micelle. Bone marrow-
derived macrophages (BMM) carried significant amounts of catalase then slowly released
the active enzyme over several days 48. The enzyme released upon stimulation of nanozyme-
loaded cell-carriers decomposed microglial hydrogen peroxide produced upon nitrated
alpha-synuclein (N-α-syn) or tumor necrosis factor alpha (TNF-α) induced activation in
vitro. Subsequent studies examined relationships between the composition of catalase
nanozyme, their physicochemical characteristics (morphology, size, and ξ-potential), and
cell loadings, release, and enzymatic activities for macrophage carriage 29.
Significant amount of catalase was detected in brains of mice after transfer of BMM loaded
with nanoformulated catalase following MPTP intoxication. It was demonstrated that such
nanozyme-loaded BMM injected into MPTP-intoxicated mice reduce neuroinflammation
and attenuate nigrostriatal degeneration 71. In particular, MPTP intoxication decreased the
number of TH-positive nigral dopaminergic neurons (32 % survival) compared to saline-
treated controls (Figure 5). In contrast, the number of surviving dopaminergic neurons in
MPTP-intoxicated mice treated with nanozyme-loaded BMM was greater than the total
number of neurons in MPTP-treated mice (62.4 % survival). Furthermore, treatment with
nanozyme alone (without cell carriers) also produced some neuroprotection effect, although
with fewer neurons (41.3 % survival) compared to the mice treated with cell/nanozyme
formulation. Finally, treatment with empty monocytes did not preserve neurons in MPTP-
intoxicated animals (31.1 % survival). This signified a neuroprotective effect of nanozyme-
loaded monocytes in MPTP-induced neurodegeneration.
The possible means by which BMM-mediated therapeutic effects of the nanozymes were
suggested (Figure 6) : 1) nanozyme-loaded BMM cross the BBB and release catalase at the
site of inflammation (particularly, in the substantia nigra pars compacta, SNpc); 2) a “depot”
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was established such that nanozyme is slowly released from BMM to the blood stream and
bypasses the BBB independently of cell-carriers; and 3) catalase nanozyme released from
BMM in the liver and spleen suppresses peripheral leukocyte activation that results in
significant protection of SNpc neurons against MPTP-induced neurodegeneration 71.
Overall, as few therapeutic modalities exist which affect progression of PD and aimed at
neuroregenerative therapies, the cell-mediated delivery of catalase and GDNF may represent
efficacious strategies that attenuate neuroinflammation and provide neuroprotection for
disease.
HIV-1 infections and neuroAIDS—NeuroAIDS is a clinical disorder that encompasses
neurologic disorders seen primarily as a consequence of damage to the central nervous
system by HIV. The clinical syndromes include cognitive, motor and behavioral disorders of
varying severity. Such syndromes affect 30 to 40% of adults and children with AIDS and,
despite the advent of potent combination antiretroviral therapy (cART), incidence rates
remain constant although disease severity is less. MP carriage has been utilized as a delivery
system for antiretroviral therapy of HIV in mice 14, 57, 81-83. To protect the drug against
degradation, as well as the cell-carriers against the drug, it was incorporated into nanosized
drug crystals (termed nano antiretroviral therapy or nanoART, Figure 7). NanoART were
made by high-pressure homogenization of crystalline drug with various poloxamer and/or
phospholipid surfactants, or by wet-milling homogenization, which produced
nanoformulations with high loading capacities (over 80%) and relatively small particle sizes
(200 to 350 nm). Scanning electron microscopy analysis revealed particles of various sizes
and morphologies, which were either polygonal, rod, cuboidal, or spherical in shape with
smooth-surfaces.
Simultaneous uptake of nanoformulated cART into the cell-carriers was shown 83. It was
also demonstrated that size, charge, coating, and shape of the nanoparticles are crucial for
efficient MP uptake, drug release, and cell migration 14. Coating of nanoART greatly
affected drug accumulation in cell-carriers. Positively-charged nanoART are taken up better
than negatively charged ones. To determine whether any of the wet-milled nanoformulations
could induce long-term antiretroviral effects, macrophages were pretreated with individual
nanoART preparations and then challenged with HIV-1ADA up to 15 days after drug
treatment. Nanoparticles loaded with atazanavir, ritonavir and indinavir were released from
macrophages and demonstrated >85, 80 and 40% inhibition, respectively, of progeny virion
production and HIV-1p24 antigen through challenge day 15. All formulations of EFV
showed almost complete suppression of viral infection 83. These results supported the
continued development of macrophage-mediated nanoART carriage for treating HIV-1
disease. In addition, delivery of antisense oligodeoxynucleotides, ribozymes, incorporated
into liposomes to HIV-1-infected cells was reported in human monocyte-derived
macrophages 84. Thus, in addition to nanoART a ribozyme complementary to HIV-1 5'-long
terminal repeat delivered in pH-sensitive liposomes inhibited virus production by 90%,
while the free ribozyme caused limited viral inhibitions.
3. Cancer
Cell-mediated delivery is also a potential therapeutic and diagnostic strategy for cancer 46,
50, 85-93. The advantage herein is that cytotoxic activity of the cell-carriers can be used in
tandem with site-specific delivery of antineoplastic agents. In addition, antineoplastic agents
are safely packaged into cell-carriers to reduce secondary cytotoxicities. However, adverse
effects of the cytotoxic drugs on the cell-carriers themselves need be considered. For
example, when nanoparticles coated with cytotoxic antibiotic, doxorubicin, were loaded into
T-cells, the release of drug inside the cell-carrier caused cell damage 94. As a result over
60% T cells loaded with the nanoparticles were dead over 15 hours after the loading.
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To overcome these limitations, mesenchymal stem cells (MSCs) were genetically
engineered to produce antitumor proteins 86, 90-93, 95. MSCs possess a set of several unique
properties, which make them ideally suited for both cellular therapies in regenerative
medicine and as vehicles for gene and drug delivery to treat cancer. These properties
include: 1) relative ease of isolation; 2) the ability to differentiate into a wide variety of
functional cell types of both mesenchymal and non-mesenchymal origin; 3) the ability to be
extensively expanded in culture without loss of differentiative capacity; 4) the
hypoimmunogenicity and even ability to produce immunosuppression upon transplantation;
5) the pronounced anti-inflammatory properties; and last but not the least, 6) the ability to
home to damaged tissues, tumors, and metastases following in vivo administration. Thus,
MSCs of human origins were genetically modified to express TNF related apoptosis-
inducing ligand (TRAIL) at the glioma tumor site. First, the retention of tumor tropic ability
of hMSC S-TRAIL cells by in vitro and in vivo migration assays was clearly demonstrated
93. Next, for the in vivo assessment of therapeutic efficacy, hMSCs were injected ipsilateral
to an established intracranial glioma tumor in a mouse xenograft model. Genetically
engineered hMSC S-TRAIL cells were effective in inhibiting intracranial U87 glioma tumor
growth (81.6%) in vivo and resulted in significantly longer animal survival.
Immunohistochemical studies demonstrated a significant, 8-fold greater tumor cell apoptosis
in the hMSC S-TRAIL-treated group compared to controls. Overall, the study demonstrated
the therapeutic efficacy of hMSC S-TRAIL cells and confirmed that hMSCs can serve as a
powerful cell-based delivery vehicle for the site-specific release of therapeutic proteins.
Furthermore, reduction of tumor growth by genetically-modified hMSCs expressing
interferon-β was reported in models of metastatic breast cancer, melanoma 86, 90, and
gliomas 95. The hMSC were also used as carriers for conditionally replicating adenoviruses
in a breast cancer metastasis model 91 and in a model of intracranial malignant glioma 92.
Attachment of nanoparticles with cytotoxic agent to the cell surface allowed cell carriers to
remain intact. Thus, NeutrAvidin-coated nanoparticles were anchored on biotinylated
plasma membrane of hMSC where they remained attached for up to two days 46. The hMSC
with such nanoparticulate patches retained their inherent tumoritropic properties in a tumor
model with a 3D-extracellular matrix. These results provide a novel strategy to actively
deliver nanostructures and therapeutics to tumors utilizing stem cells as carriers.
Besides MSCs, erythrocytes, MP, and bacterially-derived minicells were also evaluated as
carriers for delivery of antineoplastic agents. In particular, erythrocytes were used as carriers
for anticancer agent, 5-fluorouracil (5-FU), to treat malignant ascites 96. Intravenous
injections of the cell-carriers loaded with 5-FU resulted in significant regression of the
quantity of malignant ascites and the increase of survival time in mice. Notably, MP can
serve as “Trojan Horses” for nanoparticle transport into tumor regions 85, 89. Thus,
infiltration of monocytes and active delivery of Au-containing nanoparticles to the center of
tumor spheroids (which contain hypoxic centers) was reported 89. Following the delivery the
tumor spheroids were destroyed by irradiation with near-infrared light, which actuated the
delivered Au-containing nanoparticles. In another study, macrophages acted as a cellular
vehicle for 5-FU encapsulated in oligomannose-coated liposomes (OMLs) 50. The
successful decrease of tumor growth by co-administration of OML-encased 5-FU and OML-
encased magnetic nanoparticles, followed by treatment with an alternating magnetic field
was reported in a mice. These OMLs were injected into the peritoneal cavity, and then
gradually accumulated in the omentum and the other lymphoid tissues within 24 hours.
Treatment of macrophages at 39 °C for 30 min. led to the release of 5-FU from the
macrophages, suggesting that controlled release from macrophages could be achieved by
mild hyperthermia. The encased magnetic nanoparticles, which are known to convert
electromagnetic energy to heat in the OMLs allowed achieving in vivo hyperthermia.
Finally, MP were utilized for delivery of therapeutic DNA constructs into tumors 85.
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Bacterially-derived minicells with diameters of 400 nm were suggested for targeted delivery
of different chemotherapeutics and small interfering RNA (siRNA) duplexes that cause
stabilization and regression of tumor size in human cancer xenografts in mice 97, 98. The
cell-carriers were specifically targeted to tumor cell-surface proteins with biospecific
antibodies (BsAb). About 80% efficiency of packing minicells with siRNA was reported.
Thus, minicells carrying at least 12,000 siRNA molecules and 100 copies of short hairpin
RNA (shRNA)-encoding plasmid can specifically and sequentially deliver to tumor
xenografts these therapeutics and compromise drug resistance by knocking down a drug
resistance protein. This cell-mediated drug delivery system enables to use several thousand-
fold less drug than needed for conventional systemic administration of cancer therapies.
Evaluation of uptake and intracellular kinetics of minicell-delivered siRNA indicates that
after endocytosis, the minicells traverse the well-established early and late endosomal
pathways, terminating into acidified organelles, the lysosomes, where mini-cells are
degraded and release their cargo98. In addition, several methods of packaging in minicells of
a range of anticancer chemotherapeutic drugs, such as doxorubicin, paclitaxel, irinotecan, 5-
FLU, cisplatin, carboplatin monastrol, and vinblastine despite their disparate structure,
charge, hydrophobicity, and solubility were developed 99-101.
Antibody-producing hybridoma cells were used for delivery of anti-CD137 and anti-OX40
mAb 102. Microcapsules containing viable cells that secrete antibody were implanted by
injection into the subcutaneous tissue of Balb/C mice bearing CT26 colon carcinomas.
CD137 and OX40 are members of the TNF receptor family that provide costimulatory effect
on T lymphocytes. The treatment resulted in complete tumor eradication in an elevated
fraction of cases and strong tumor-specific cytotoxic T lymphocyte responses with either
anti-CD137 or anti-OX40 producing hybridomas.
Besides cytotoxic agents, delivery of imaging agents is of importance for cancer therapy.
MP-mediated delivery of quantum dots to brain tumors was explored for this purpose 103.
Thus, the surgical management of brain tumors requires the precise localization of tumor
tissues within normal brain parenchyma in order to achieve accurate diagnostic biopsy and
complete surgical resection. To this end, quantum dots are optical semiconductor
nanocrystals that exhibit stable, bright fluorescence. It was demonstrated that the
intravenous injection of quantum dots is accompanied by reticuloendothelial system and
macrophage sequestration. Macrophages infiltrate brain tumors and phagocytize
intravenously injected quantum dots, optically labeling the tumors.
Another class of imaging agents, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-
gadolinium (Gd) chelates, were used for enhanced magnetic resonance imaging (MRI) of
macrophage-mediated malignancies 104. To increase the nanoparticles uptake in
macrophages, copolymers were vectorized with mannosamine, which was shown to increase
mannose receptor mediated uptake in human MP. It was suggested that intravenously
administered GD-nanoparticles will be accumulated in macrophages and then transported to
the pathological sites (e.g., solid tumor). Overall, the tumor recruitment of inflammatory-
response cells may be exploited for cell-mediated delivery of antineoplastic and imaging
agents.
4. Lung Injury
Drug delivery to small airways, terminal bronchioles and alveoli is complicated due to the
methodological limitations in targeting the deep lung with high efficiency drug distribution
to the site of pathology. To overcome these limitations, chitosan nanoparticles with
entrapped curcumin (an anti-inflammatory compound) was loaded into Testis-derived
Sertoli cells and then injected intravenously into mice with bronchial or alveolar injuries105.
By 24-hours post-injection, most of the curcumin load (~90%) delivered in the injected
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Sertoli cells was present and distributed throughout the lungs including the perialveloar sac
area in the lower lungs. These results identify a novel and efficient method for targeted
delivery of drugs for treatment of bronchitis and alveolitis. In addition, lungs are suitable for
both local and systemic drug delivery, therefore this route may be used broadly for other
diseases.
5. Microbial Infections
The efficiency of antifungal agents has been diminished by their severe side effects and poor
pharmacokinetics. To this end, erythrocytes were suggested as delivery vehicles for
antifungal agent, amphotericin B (AmB). In order to avoid toxic effects and achieve efficient
drug loading, AmB was encapsulated in nanosuspension (AmB-NS) by high-pressure
homogenization 106. AmB-NS was loaded into RBC by using hypotonic hemolysis, leading
to intracellular AmB amounts of 3.81 +/- 0.47 pg RBC-1 and an entrapment efficacy of
15-18%. Hence, RBC served as primary carriers. Then, the uptake of RBC loaded with
AmB-NS by leucocytes was studied by flow cytometry. More than 98% of the phagocyte
population (granulocytes and peripheral monocytes accumulated AmB-NS after four hours
of incubation, and then showed a slow AmB release over ten days without any alteration in
cell viability. This results in an immediate, permanent inhibition of intra- and extracellular
fungal activity. AmBNS-RBC-leukocyte-mediated delivery of AmB was efficient in
amounts 1000 times lower than the toxic dose.
Another antifungal agent, chloroquine, loaded into phosphatidylserine-containing negatively
charged liposomes was used in MP-mediated delivery against C. neoformans infection in the
mouse brain 107. Administration of chloroquine-loaded liposomes accumulated inside
macrophage phagolysosomes resulted in a remarkable reduction in fungal load in the brain
even in low doses compared to free drug in high doses thus increasing antifungal activity of
macrophages. Therefore, this drug-delivery method is effective for the transport of water-
insoluble substances, such as AmB, and this warrants consideration for further testing.
6. Epilepsy
Relatively straightforward method of engineered adenosine-releasing cells was developed
for treatment of epilepsy 108. Lack of adenosine, a modulator of neuronal activity with
anticonvulsant and neuroprotective properties, was found to contribute to ictogenesis.
Therefore, focal reconstitution of adenosine within an epileptogenic brain region constitutes
a rational therapeutic approach, whereas systemic augmentation of adenosine is precluded
by side effects. To this end, human mesenchymal stem cells and human embryonic stem
cells were embedded in a cell-encapsulation device to release adenosine and reduce acute
injury and seizures, as well as chronic seizures 108. Human embryonic stem cells (hESCs)
have a high proliferative capacity and can be subjected to specific cellular differentiation
pathways. hESCs, differentiated in vitro into neuroepithelial cells and grafted into the mouse
brain, displayed intrahippocampal location and neuronal morphology. Overall, this
therapeutic approach demonstrated antiepileptic and neuroprotective properties when grafted
into the mouse hippocampus. The therapeutic potential of this approach suggests the
feasibility to engineer autologous adenosine-releasing stem cells derived from a patient 109.
7. Expert Opinion
The concept of using cells as drug delivery vehicles is under development. Challenges
include sufficient loading capacity and triggered drug release, preservation of therapeutic
agents against degradation inside the cells, protection of cell-carriers from drug cytotoxic
effects, and efficient homing of cells to the disease site. In addition, harvesting of cells
sufficient quantities or their expansion is also important issue.
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Two different approaches are utilized in cell-mediated drug delivery. First, cell-carriers
(predominantly MP) are genetically modified to produce therapeutically active molecules.
Second, host cells are loaded with a drug usually incorporated into protective container, and
then used as “Trojan horses” to deliver the drug to the disease side (Figure 8). Most of cell-
based delivery systems suggest the unloading the therapeutic agent at the disease site.
However, a few utilized another approach, when the targeted cells accumulate the carrier
along with the drug (mini-cells with anticancer agents and red blood cells with antifungal
agents).
Regarding the first approach, the ideal cell delivery vehicle would be stable in tissue culture
and capable of sustained, preferably regulated expression of therapeutic molecules. The cells
should have appropriate and predictable differentiation pattern and survive long time in vivo
after transplantation. Obviously, for both approaches, the cell carriers should demonstrate
responsiveness to the chemotactic signals produced by the type of pathology that they are
used to treat. Regarding the second approach, loading cell-carriers with drug in the blood
stream by injecting nanoparticlular drug targeted to these cells is the most attractive strategy.
To this end, it is important to note that these cells are moving targets. Nanosystems that bind
to these targets are potentially a powerful approach for imaging their movement and
delivering a therapeutic drug dose to the disease site. Clearly, a multifunctional molecular
scaffold that is aimed at delivery of drug specifically to the cell-carrier, but in addition could
be engineered for imaging purposes would offer substantial benefits over current
approaches.
Such strategy is opposite to the common approach when drug-loaded nanoparticles are
designed to minimize their entrapment in reticulo-endothelail system and avoid drug
decomposition and clearance. Consequently, design of nanocarriers for cell-mediated drug
delivery (size, shape, surface charge, etc.) may differ from those used for conventional drug
delivery systems. Nevertheless, engaging different defense mechanisms into drug delivery
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Types of nanocarriers for drug delivery. A: liposomes; B: polymer and lipid nanoparticles;
C: nanospheres and nanocapsules; D: nanosuspensions; E: polymer micelles; F: nanogels;
G: block ionomer complexes; H: nanofibers and nanotubes. Used with permission 110.
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Figure 2. Schematic representation of SA-PEGFITC/PAMAM construction
A. The construction of streptavidin-PEGFITC/PAMAM. B. Absorbance profiles of
streptavidin-PEGFITC/PAMAM and PEGFITC/PAMAM. C. Reverse-phase HPLC of
SAPEGFITC/PAMAM and PEGFITC/PAMAM. Used with permission 39.
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Figure 3. Optimization of nanocarriers structure for catalase delivery in macrophages
Nanozymes consisting of catalase and a negatively charged block copolymer demonstrate
low toxicity, high loading capacity and release from BMM, however provide limited
protection of the enzyme against protease degradation inside the cell-carriers. Nanozymes
based on positively charged block copolymers, especially the PLs, showed increased
cytotoxicity and low loading and release rates, but were highly protective of catalase.
Furthermore, nanozymes with PEG corona show good stability in water, limited cytoxicity
and efficient protection of catalase, but decreased loading capacity and cell release. The
optimal nanozyme formulation is one based on positively charged block copolymers (PEI-
PEG/catalase and PL-PEG/catalase). Used with permission 29.
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Figure 4. Using neural stem cells for drug delivery to CNS
Neural stem cells are attracted by at least three physiological processes that are common to
many brain pathologies: inflammation, reactive astrocytosis and angiogenesis. Pathology-
induced CNS inflammation is mediated by activated microglia that release cytokines and
chemokines, which, in turn, increases the inflammatory reaction. The brain lesion and
subsequent inflammation trigger reactive astrocytosis. The lesion-induced angiogenesis and
inflammation-activated endothelial cells enhance neural stem cell homing to brain pathology
by secreting chemoattractant factors, and also offer an atypical, perivascular niche for
support of immigrating neural stem cells. Used with permission 66.
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Figure 5. Neuroprotective effect of nanozyme-loaded BMM in an MPTP model of PD
MPTP-intoxicated C57Bl/6 mice (18 mg/kg) were intravenously injected with saline
(second bar), nanozyme alone (third bar), macrophages loaded with nanozyme (5×106 cells/
mouse/100μl) (fourth bar), or empty macrophages (fifth bar). Healthy non-intoxicated
animals were used as control group (first bar). Seven days after treatment the animals were
sacrificed; brain slices were stained for tyrosine hydroxylase-positive nigral dopaminergic
neurons (A). Results from N = 5 animals per group demonstrate a significant loss of
nigrostratial neurons in MPTP treated mice, which is prevented by adoptive transfer of
macrophages loaded with nanozyme (B). No significant neuroprotective effect was detected
after treatment with nanozyme alone, or empty macrophages. Values are means ± SEM, and
P < 0.05 compared with asaline; bMPTP; cMPTP+macrophage/nanozyme. Used with
permission 71.
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Figure 6. A pictorial scheme for cell-based nanoformulated drug delivery
Three possible ways of BMM-mediated therapeutic effects of catalase nanozyme in PD
mouse model: Pathway I: BMM loaded with nanozyme cross the BBB and release catalase
in the SNpc; Pathway II: nanozyme is released from BMM to the blood stream and
bypasses the BBB independently of cell-carriers; Pathway III: catalase nanozyme released
from BMM in the liver and spleen suppresses peripheral leukocyte activation that results in
significant protection of nigrostratial neurons against MPTP-induced neurodegeneration.
Used with permission 71.
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(A) NanoART of antiretroviral agents were prepared by high-pressure homogenization using
an AvestinC-5 homogenizer; (B) scanning-electron microscopy demonstrated different
nanoparticle morphology; (C) uptake of drug-loaded nanoART (red) in monocyte-derived
macrophages (green); (D) cells treated with nanoART showed complete or near complete
suppression of HIV1 p24 antigen production; (E) biodistribution of nanoART in mice
following intravenious injections; (F) patient treatment with nanoART in clinical settings.
Used with permission 111.
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Cell-based Drug Delivery Systems.
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Table 1
Examples of cell-mediated drug delivery systems
Type of cell-carrier Therapeutic agent Rote of administration1 References
Alziemer's disease
Neural stem cells (NSCs) ciliary neurotrophic factor (NTFs) i.c. 73
NSCs nerve growth factor (NGF) i.c. 65
NSCs brain-derived neurotropic factor (BDNF) i.c. 64, 75
NSCs choline acetyltransferase (ChAT) i.c. 72, 74
Parkinson's disease
Monocytes, macrophages catalase i.v. 29, 48, 71
Fetal dopamine neurons dopamine i.c. 76
NSCs glial cell-line derived neurotropic factor (GDNF) i.c. 77, 80
NSCs vascular endothelial growth factor (VGEF) i.c. 78, 79
HIV-1 infection and neuroAIDS
Monocytes, macrophages atazanavir, ritonavir, indinavir i.v. 14, 81-83
Cancer
T-cells doxorubicin In vitro 94
Mesenchymal stem cells (MSCs) tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)
ipsilateral 93
MSCs interferon-β i.v. 86, 90, 95
MSCs oncolytic adenovirus i.v. 91, 92
MSCs antineoplastic agent In vitro, in 3D collagen gels 46
Erythrocytes 5-fluorouracil i.v. 96
Monocytes and macrophages Au-containing nanoparticles In vitro, in spheroids 85, 89
Introperitoneal macrophages 5-fluorouracil i.p. 50
Bacterially-derived mini-cells small interfering RNA (siRNA), cytotoxic drugs i.v., i.t. 97, 98
Bacterially-derived mini-cells doxorubicin i.v., i.t. 98




Hybridoma cell lines 2A and OX86 anti-CD137 and anti-OX40 mAb s.c. 102
Inflammation
Macrophages betamethasone phosphate in situ 25
Erythrocytes glycoprotein A 25
Sertoli cells anti-inflammatory agent, curcumin i.v. 105
Microbial Infections
Erythrocytes antifungal agent, amphotericin B in viro 106
Macrophages chloroquine i.v. 107













Batrakova et al. Page 28
Type of cell-carrier Therapeutic agent Rote of administration1 References
Epilepsy
Human MSCs and human embryonic
stem cells
adenosine i.c. in cell-encapsulation device 108, 109
1
i.c., intracranial; i.v., intravenous; i.p., intraperitoneal; i.t., intratumoral; s.c., subcutaneous injections.
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